The University of Oxford is testing the anti-parasitic drug ivermectin as a possible treatment for Covid-19, as part of a British government-backed study that aims to aid recoveries in non-hospital settings.
Drugmaker Merck & Co. Inc. said the company’s analysis of available data does not support the safety and efficacy of the anti-parasite medicine ivermectin for the treatment of Covid-19.
South Korean drugmaker Daewoong Pharmaceutical Co. Ltd. received regulatory approval for Phase 1 clinical trials of the company’s anti-parasitic niclosamide drug to treat Covid-19 patients.